Suppressor of cytokine signaling-3 is recruited to the activated granulocyte-colony stimulating factor receptor and modulates its signal transduction

Journal of Immunology

Volumn 169, Issue 3, 2002, Pages 1219-1227

  Hörtner, Michael ^a   Nielsch, Ulrich ^a   Mayr, Lorenz M ^a   Johnston, James A ^a   Heinrich, Peter C ^a   Haan, Serge ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; PHOSPHOTYROSINE; STAT PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; BONE MARROW CELL; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SURFACE PLASMON RESONANCE;

EID: 0036681955     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.169.3.1219     Document Type: Article

References (56)

1. Granulocyte colony-stimulating factor and its receptor
2. Molecular analysis of the granulocyte colony-stimulating factor receptor
3. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granuloyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization
4. Impaired production and increased apoptosis of neutrophils in granuloyte colony-stimulating factor receptor-deficient mice
5. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: Studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), intelieukin-3 (IL-3) and Fit-3 ligand (Flt3L)
6. Infantile genetic agranulocytosis
7. Monosomy 7 and activating PAS mutations accompany malignant transformation in patients with congenital neutropenia
8. Safety of long-term administration of granulocyte colony-stimulating factor for severe chronic neutropenia
9. Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia
10. Clinical relevance of point mutations in the cytoplasmic domain of the granulocyte colony-stimulating factor receptor gene in patients with severe congenital neutropenia
11. Identification of a nonsense mutation in the granulocyte-colony-stimulating factor receptor in severe congenital neutropenia
12. Tyrosine kinase JAK1 is associated with the granulocyte-colony-stimulating factor receptor and both become tyrosine-phosphorylated after receptor activation
13. ras route
14. Jak1 plays an essential role for receptor phosphorylation and Stat activation in response to granulocyte colony-stimulating factor
15. Aberrant activation of JAK/STAT pathway components in response to G-CSF, interferon-α/β and interferon 7 in NFS-60 cells
16. Rapid activation of the STAT3 transcription factor by granulocyte colony-stimulating factor
17. Involvement of STAT3 in the granulocyte colony-stimulating factor-induced differentiation of myeloid cells
18. Stimulation of Stat5 by granulocyte colony-stimulating factor (G-CSF) is modulated by two distinct cytoplasmic regions of the G-CSF receptor
19. The Src-like tyrosine kinase Hck is activated by granulocyte colony-stimulating factor (G-CSF) and docks to the activated G-CSF receptor
20. The SH2 domain-containing protein tyrosine phosphatase SHP-1 is induced by granulocyte colony-stimulating factor (G-CSF) and modulates signaling from the G-CSF receptor
21. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phospborylated interleukin 3 and erythropoietin receptors
22. A family of cytokine-inducible inhibitors of signalling
23. Structure and function of a new STAT-induced STAT inhibitor
24. A new protein containing an SH2 domain that inhibits JAK kinases
25. Twenty proteins containing a C-terminal SOCS hox form five structural classes
26. Cloning and characterization of novel CIS family genes
27. Cloning and functional analysis of new members of STAT induced STAT inhibitor (SSI) family: SSI-2 and SSI-3
28. The elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families
29. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation
30. Thrombopoietin induces an SH2-containing protein, CIS1, which binds to Mp1: Involvement of the ubiquitin proteosome pathway
31. SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130
32. Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130
33. Improved retroviral vectors for gene transfer and expression
34. STAT structure and function in signaling
35. src Src homology 2 domain binding to lyrosine-phosphorylated peptides determined by a competition assay or surface plasmon resonance
36. SOCS-3 is tyrosine phosphorylated in response to interleukin-2 and suppresses STAT5 phosphorylation and lymphocyte proliferation
37. CIS3/SOCS-3 suppreses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2
38. Identification of the Y985 and Y1077 motifs as SOCS3 recruitment sites in the murine leptin receptor
39. 985
40. Cytokine receptor expression on hematopoietic stem and progenitor cells
41. Differential effects of human granulocyte colony-stimulating factor (hG-CSF) and thrombopoietin on megakaryopoiesis and platelet function in hG-CSF receptor-transgenic mice
42. Direct binding of Shc, Grb2, SHP-2 and p40 to the murine granulocyte colony-stimulating factor receptor
43. Tyrosine residues in the granulocyte colony-stimulating factor (G-CSF) receptor mediate G-CSF-induced differentiation of murine myeloid leukemic (MI) cells
44. ras/MAP kinase signalling pathway
45. Activation of Akt kinase by granulocyte colony-stimulating factor (G-CS F): Evidence for the role of a tyrosine kinase activity distinct from the Janus kinases
46. Phosphatidylinositol 3′-kinase and SH2-containing inositol phosphatase (SHIP) are recruited by distinct positive and negative growth-regulatory domains in the granulocyte colony-stimulating factor receptor
47. Growth hormone preferentially induces the rapid, transient expression of SOCS-3, a novel inhibitor of cytokine receptor signaling
48. Induction of JAB/SOCS-1/SS1-1 and C1S3/SOCS-3/SS1-3 is involved in gp130 resistance in cardiovascular system in rat treated with cardiotrophin-1 in vivo
49. Insulin induction of SOCS-2 and SOCS-3 mRNA expression in C2C12 skeletal muscle cells is mediated by Stat5
50. Multiple signaling pathways induced by granulocyte colony-stimulating factor involving activation of JAKs, STAT5, and/or STAT3 are required for regulation of three distinct classes of immediate early genes
51. STAT-3 activation is required for normal G-CSF-dependent proliferation and granulocytic differentiation
52. A new high affinity binding site for suppressor of cytokine signaling-3 on the erythropoietin receptor
53. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop
54. A randomized controlled phase 111 trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia
55. Sustained receptor activation and hyperproliferation in response to granulocyte colony-stimulating factor (G-CSF) in mice with a severe congenital neutropenia/acute myeloid leukemia-derived mutation in the G-CSF receptor gene
56. SHP2 and SOCS3 contribute to Y759 dependent attenuation of IL-6-signaling-through gp130